Home Cart 0 Sign in  
X

[ CAS No. 199177-26-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 199177-26-9
Chemical Structure| 199177-26-9
Chemical Structure| 199177-26-9
Structure of 199177-26-9 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 199177-26-9 ]

Related Doc. of [ 199177-26-9 ]

Alternatived Products of [ 199177-26-9 ]

Product Details of [ 199177-26-9 ]

CAS No. :199177-26-9 MDL No. :MFCD06797981
Formula : C7H5BrO2 Boiling Point : -
Linear Structure Formula :- InChI Key :XVFGERBEZKEGSS-UHFFFAOYSA-N
M.W : 201.02 Pubchem ID :16641084
Synonyms :

Calculated chemistry of [ 199177-26-9 ]

Physicochemical Properties

Num. heavy atoms : 10
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.0
Num. rotatable bonds : 1
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 41.55
TPSA : 37.3 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.75 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.35
Log Po/w (XLOGP3) : 2.5
Log Po/w (WLOGP) : 1.97
Log Po/w (MLOGP) : 1.55
Log Po/w (SILICOS-IT) : 2.18
Consensus Log Po/w : 1.91

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.04
Solubility : 0.184 mg/ml ; 0.000913 mol/l
Class : Soluble
Log S (Ali) : -2.93
Solubility : 0.237 mg/ml ; 0.00118 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.63
Solubility : 0.473 mg/ml ; 0.00236 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.36

Safety of [ 199177-26-9 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 199177-26-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 199177-26-9 ]
  • Downstream synthetic route of [ 199177-26-9 ]

[ 199177-26-9 ] Synthesis Path-Upstream   1~11

  • 1
  • [ 626-41-5 ]
  • [ 68-12-2 ]
  • [ 199177-26-9 ]
YieldReaction ConditionsOperation in experiment
50.12%
Stage #1: With n-butyllithium In tetrahydrofuran at -78℃; for 0.583333 h;
Stage #2: at -78 - 20℃; for 1.5 h;
Step-1 : Synthesis of 3-bromo-5-hydroxybenzaldehyde: [0135] To a solution of 3, 5-dibromophenol (2.5 g, 9.92 mmol) in THF (25 mL) at -78 °C was added a 2.5 M solution of n-BuLi (7.9 mL, 19.84 mmol) dropwise over a period of 15 min. The yellow solution was stirred at the same temperature for 20 min, followed by dropwise addition of dry DMF (15.29 mL, 198.4 mmol). The reaction mixture was stirred at - 78 °C for 30 min and then at RT for 1 h. The reaction was quenched with saturated ammonium chloride solution (200 mL) and extracted with EtOAc (3x250 mL). The organic layer was dried over sodium sulfate, concentrated under reduced pressure and purified by column chromatography (Silica gel: 100-200 mesh, Elution: 0-6percent EtOAc in hexane) to yield the desired compound, 3-bromo-5-hydroxybenzaldehyde (1.0 g, 50.12percent) as a white solid. HNMR (400 MHz, DMSO-d6): δ (ppm): 10.5 (bs, 1H), 9.85 (s, 1H), 7.50 (s, 1H), 7.25 (d, 2H).
50%
Stage #1: With n-butyllithium In tetrahydrofuran; hexane at -78℃; for 0.5 h;
Stage #2: at -78 - 20℃; for 2.5 h;
A solution of 3,5-dibromophenol (2.5 g, 10 mmol) in THF (25 mL) was cooled to -78 C using the dry ice-acetone bath and a solution of BuLi (9 mL, 22.5 mmol, 2.5 M solution in hexane) was added dropwise. The reaction mixture was stirred for 30 min at this temperature and DMF (15.3 mL) was added. The solution was stirred for 30 min at -78 °C and for 2 h at r. t. The reaction was quenched with sat. NH4C1 and extracted with EtOAc (3 times). The combined organic layers were dried over Na2S04, filtered and concentrated under reduced pressure. The residue was separated by column chromatography (hexane : EtOAc = 20 : 1 to 4 : 1) yielding 1.0 g (50percent) of a desired product. - 1H NMR (300 MHz, DMSO-d6) 10.55 - 10.39 (m, 1 H), 9.89 (s, 1 H), 7.53 - 7.50 (m, 1 H), 7.29 - 7.24 (m, 2 H). Spectral data are identical to those published in the literature (Yang et al., 2016)
Reference: [1] Patent: WO2015/184405, 2015, A1, . Location in patent: Paragraph 0135; 0141; 0148; 0154; 0160; 0166; 0173; 0184
[2] Angewandte Chemie - International Edition, 2017, vol. 56, # 49, p. 15746 - 15750[3] Angew. Chem., 2017, vol. 129, p. 15952 - 15957,6
[4] Patent: WO2018/114965, 2018, A1, . Location in patent: Page/Page column 26
[5] Patent: WO2008/58387, 2008, A1, . Location in patent: Page/Page column 20
[6] Patent: WO2010/66028, 2010, A1, . Location in patent: Page/Page column 27
[7] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 8, p. 2430 - 2436
[8] Patent: WO2009/140769, 2009, A1, . Location in patent: Page/Page column 34
[9] Patent: WO2008/141462, 2008, A1, . Location in patent: Page/Page column 35-36
[10] Patent: WO2009/135299, 2009, A1, . Location in patent: Page/Page column 54
  • 2
  • [ 936844-19-8 ]
  • [ 199177-26-9 ]
YieldReaction ConditionsOperation in experiment
80% With sulfuric acid; acetic acid; sodium nitrite In water at 0℃; for 3 h; Reflux To a solution of 15 (0.71 g, 6.0 mmol) in AcOH/H2SO4/H2O(5.0 mL, 8/1/1) was added sodium nitrite aqueous solution (0.24 g,3.5 mmol, 1 mL) dropwise and stirred for 1 h at 0 C. The reactionwas added 10percent sulphuric acid (20 mL) and refluxed for 2 h. Aftercooling to the room temperature, the reaction mixture wasextracted with EtOAc (3 30 mL), washed with saturated sodiumbicarbonate solution (3 30 mL) and brine (30 mL). The combinedorganic layers were dried over Na2SO4 and concentrated. The residue was purified by column chromatography (EtOAc/petroleumether, 1/8) to give 16 (0.47 g, 80percent) as a pale yellow solid. 1H NMR(300 MHz, DMSO-d6) d: 10.43 (s, 1H), 9.88 (s, 1H), 7.51 (s, 1H),7.31e7.18 (m, 2H).
Reference: [1] European Journal of Medicinal Chemistry, 2016, vol. 116, p. 46 - 58
[2] Journal of the American Chemical Society, 2007, vol. 129, # 15, p. 4512 - 4513
  • 3
  • [ 262450-65-7 ]
  • [ 199177-26-9 ]
Reference: [1] Patent: US2005/239881, 2005, A1, . Location in patent: Page/Page column 44-45
[2] Patent: US2007/78128, 2007, A1, . Location in patent: Page/Page column 21
[3] Patent: US2008/20981, 2008, A1, . Location in patent: Page/Page column 20-21
[4] Patent: US2008/45511, 2008, A1, . Location in patent: Page/Page column 20-21
[5] Patent: US2009/170856, 2009, A1, . Location in patent: Page/Page column 22
[6] Patent: US2004/198736, 2004, A1, . Location in patent: Page/Page column 82
[7] Patent: US2006/25462, 2006, A1, . Location in patent: Page/Page column 18
  • 4
  • [ 1020336-51-9 ]
  • [ 199177-26-9 ]
YieldReaction ConditionsOperation in experiment
1.85 g With pyridinium chlorochromate In dichloromethane at 20℃; for 1 h; Borane-methyl sulfide complex (5.53 ml, 1 1 mmol) was slowly added to a mixture of 3-bromo-5-hydroxybenzoic acid (2 g, 9.22 mmol) and trimethyl borate (2.1 ml, 18 mmol) in tetrahydrofuran (10 ml). The mixture was stirred at room temperature overnight. Methanol (25 ml) was then added and the solvents removed. Dichloromethane (60 ml) and then pyridinium chlorochromate (3.77 g, 17 mmol) were added to the crude and the mixture was stirred at room temperature for an hour. The crude was filtered and the mother liquor concentrated in vaccuo. The residue was purified by reverse phase to give 1.85 g (51 percent yield) of the title compound as a white solid. Purity 99percent. LRMS (m/z): 200 (M-1 )"
Reference: [1] Journal of Medicinal Chemistry, 2013, vol. 56, # 8, p. 3217 - 3227
[2] Patent: WO2014/60431, 2014, A1, . Location in patent: Page/Page column 106
[3] Bioorganic and Medicinal Chemistry, 2018, vol. 26, # 11, p. 2937 - 2957
  • 5
  • [ 68-12-2 ]
  • [ 199177-26-9 ]
Reference: [1] Patent: WO2007/9250, 2007, A1, . Location in patent: Page/Page column 47-48
  • 6
  • [ 936844-18-7 ]
  • [ 199177-26-9 ]
Reference: [1] Journal of the American Chemical Society, 2007, vol. 129, # 15, p. 4512 - 4513
[2] European Journal of Medicinal Chemistry, 2016, vol. 116, p. 46 - 58
  • 7
  • [ 355134-13-3 ]
  • [ 199177-26-9 ]
Reference: [1] Journal of the American Chemical Society, 2007, vol. 129, # 15, p. 4512 - 4513
[2] European Journal of Medicinal Chemistry, 2016, vol. 116, p. 46 - 58
  • 8
  • [ 99-61-6 ]
  • [ 199177-26-9 ]
Reference: [1] Journal of the American Chemical Society, 2007, vol. 129, # 15, p. 4512 - 4513
[2] European Journal of Medicinal Chemistry, 2016, vol. 116, p. 46 - 58
  • 9
  • [ 909854-23-5 ]
  • [ 199177-26-9 ]
Reference: [1] Journal of the American Chemical Society, 2007, vol. 129, # 15, p. 4512 - 4513
  • 10
  • [ 140472-69-1 ]
  • [ 199177-26-9 ]
Reference: [1] Journal of Medicinal Chemistry, 2013, vol. 56, # 8, p. 3217 - 3227
[2] Patent: WO2014/60431, 2014, A1,
[3] Bioorganic and Medicinal Chemistry, 2018, vol. 26, # 11, p. 2937 - 2957
  • 11
  • [ 199177-26-9 ]
  • [ 74-88-4 ]
  • [ 262450-65-7 ]
YieldReaction ConditionsOperation in experiment
91% With sodium hydride In N,N-dimethyl-formamide at 0 - 20℃; Example 1 5A: 3 -Bromo-5-methoxybenzaldehyde j00295j 3-Bromo-5-hydroxybenzaldehyde (0.5 g, 2.487 mmol) was dissolved in DMF(14.63 mL) and cooled to 0 °C. NaH (0.119 g, 4.97 mmol) was added in three portions.The flask was immediately allowed to warm to ambient temperature and Mel (0.93 3 mL,14.92 mmol) was added, and the reaction stirred overnight. The reaction was diluted with water and partially concentrated in vacuo. The material was diluted with DCM and washed twice with water, washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo. The crude material was purified by silica gel column chromatography (gradientfrom 0 to 100percent EtOAc in hexanes) to yield Example 15A (0.488 g, 2.27 mmol, 9 1percent).‘H NMR (400 MHz, CHLOROFORM-cl) ö ppm 9.91 (1 H, s), 7.58 (1 H, t, J=1.38 Hz), 7.28 - 7.35 (2 H, m, J=2.38, 2.13, 2.01, 2.01 Hz), 3.86 (3 H, s).
Reference: [1] Patent: WO2014/201073, 2014, A1, . Location in patent: Paragraph 00295
[2] ACS Medicinal Chemistry Letters, 2017, vol. 8, # 1, p. 67 - 72
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 199177-26-9 ]

Aryls

Chemical Structure| 1427438-58-1

[ 1427438-58-1 ]

4-Bromo-2-hydroxy-6-methylbenzaldehyde

Similarity: 0.96

Chemical Structure| 22532-60-1

[ 22532-60-1 ]

2-Bromo-4-hydroxybenzaldehyde

Similarity: 0.93

Chemical Structure| 22532-62-3

[ 22532-62-3 ]

4-Bromo-2-hydroxybenzaldehyde

Similarity: 0.93

Chemical Structure| 262450-65-7

[ 262450-65-7 ]

3-Bromo-5-methoxybenzaldehyde

Similarity: 0.92

Chemical Structure| 1761-61-1

[ 1761-61-1 ]

5-Bromo-2-hydroxybenzaldehyde

Similarity: 0.91

Bromides

Chemical Structure| 1427438-58-1

[ 1427438-58-1 ]

4-Bromo-2-hydroxy-6-methylbenzaldehyde

Similarity: 0.96

Chemical Structure| 22532-60-1

[ 22532-60-1 ]

2-Bromo-4-hydroxybenzaldehyde

Similarity: 0.93

Chemical Structure| 22532-62-3

[ 22532-62-3 ]

4-Bromo-2-hydroxybenzaldehyde

Similarity: 0.93

Chemical Structure| 262450-65-7

[ 262450-65-7 ]

3-Bromo-5-methoxybenzaldehyde

Similarity: 0.92

Chemical Structure| 1761-61-1

[ 1761-61-1 ]

5-Bromo-2-hydroxybenzaldehyde

Similarity: 0.91

Aldehydes

Chemical Structure| 1427438-58-1

[ 1427438-58-1 ]

4-Bromo-2-hydroxy-6-methylbenzaldehyde

Similarity: 0.96

Chemical Structure| 22532-60-1

[ 22532-60-1 ]

2-Bromo-4-hydroxybenzaldehyde

Similarity: 0.93

Chemical Structure| 22532-62-3

[ 22532-62-3 ]

4-Bromo-2-hydroxybenzaldehyde

Similarity: 0.93

Chemical Structure| 262450-65-7

[ 262450-65-7 ]

3-Bromo-5-methoxybenzaldehyde

Similarity: 0.92

Chemical Structure| 1761-61-1

[ 1761-61-1 ]

5-Bromo-2-hydroxybenzaldehyde

Similarity: 0.91